A broad comparative genomics approach to understanding the pathogenicity of Complex I mutations.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
01 10 2021
Historique:
received: 16 05 2021
accepted: 01 09 2021
entrez: 2 10 2021
pubmed: 3 10 2021
medline: 28 12 2021
Statut: epublish

Résumé

Disease caused by mutations of mitochondrial DNA (mtDNA) are highly variable in both presentation and penetrance. Over the last 30 years, clinical recognition of this group of diseases has increased. It has been suggested that haplogroup background could influence the penetrance and presentation of disease-causing mutations; however, to date there is only one well-established example of such an effect: the increased penetrance of two Complex I Leber's hereditary optic neuropathy mutations on a haplogroup J background. This paper conducts the most extensive investigation to date into the importance of haplogroup context in the pathogenicity of mtDNA mutations in Complex I. We searched for proven human point mutations across more than 900 metazoans finding human disease-causing mutations and potential masking variants. We found more than a half of human pathogenic variants as compensated pathogenic deviations (CPD) in at least in one animal species from our multiple sequence alignments. Some variants were found in many species, and some were even the most prevalent amino acids across our dataset. Variants were also found in other primates, and in such cases, we looked for non-human amino acids in sites with high probability to interact with the CPD in folded protein. Using this "local interactions" approach allowed us to find potential masking substitutions in other amino acid sites. We suggest that the masking variants might arise in humans, resulting in variability of mutation effect in our species.

Identifiants

pubmed: 34599203
doi: 10.1038/s41598-021-98360-7
pii: 10.1038/s41598-021-98360-7
pmc: PMC8486755
doi:

Substances chimiques

Electron Transport Complex I EC 7.1.1.2

Types de publication

Journal Article Meta-Analysis

Langues

eng

Sous-ensembles de citation

IM

Pagination

19578

Informations de copyright

© 2021. The Author(s).

Références

Hum Mutat. 2015 May;36(5):569-71
pubmed: 25764011
Genome Biol Evol. 2017 May 1;9(5):1341-1350
pubmed: 28595327
Brain. 2001 Jan;124(Pt 1):209-18
pubmed: 11133798
Hum Mutat. 2011 Nov;32(11):1319-25
pubmed: 21882289
J Biol Chem. 2007 Dec 21;282(51):36845-52
pubmed: 17940288
PLoS One. 2017 Nov 21;12(11):e0187862
pubmed: 29161289
Ann N Y Acad Sci. 2004 Apr;1011:7-20
pubmed: 15126279
PLoS Genet. 2011 Mar;7(3):e1001319
pubmed: 21408205
Mol Genet Metab. 2015 Sep-Oct;116(1-2):4-12
pubmed: 26095523
Science. 2016 Apr 1;352(6281):54-61
pubmed: 26917594
J Biol Chem. 2009 Apr 10;284(15):9814-23
pubmed: 19189973
J Med Genet. 2006 Feb;43(2):175-9
pubmed: 15972314
Nat Genet. 2004 Nov;36(11):1207-12
pubmed: 15502829
Bioinformatics. 2009 Jun 1;25(11):1422-3
pubmed: 19304878
Am J Primatol. 2020 Apr;82(4):e23092
pubmed: 31960516
J Mol Evol. 1979 Mar 15;12(3):219-36
pubmed: 439147
PeerJ. 2017 Dec 12;5:e4143
pubmed: 29250469
Genetics. 2018 Apr;208(4):1535-1552
pubmed: 29496745
PLoS One. 2017 May 16;12(5):e0177403
pubmed: 28510580
J Mol Evol. 2005 Oct;61(4):491-7
pubmed: 16132471
Ann Neurol. 2015 May;77(5):753-9
pubmed: 25652200
Mol Biol Evol. 2007 Aug;24(8):1586-91
pubmed: 17483113
Trends Genet. 2006 Nov;22(11):603-7
pubmed: 16979783
Proc Natl Acad Sci U S A. 2005 Apr 5;102(14):4990-5
pubmed: 15784738
Hum Mutat. 2009 Feb;30(2):E386-94
pubmed: 18853457
PLoS Biol. 2008 Jan;6(1):e10
pubmed: 18232733
J Mol Evol. 2018 Jul;86(6):395-403
pubmed: 29987491
PLoS Genet. 2018 Nov 6;14(11):e1007735
pubmed: 30399141
Hum Mol Genet. 2006 Sep 1;15(17):2543-52
pubmed: 16849371
J Inherit Metab Dis. 2010 Dec;33 Suppl 3:S95-104
pubmed: 20135231
Nat Methods. 2010 Apr;7(4):248-9
pubmed: 20354512
Graefes Arch Clin Exp Ophthalmol. 2021 Sep;259(9):2461-2472
pubmed: 33185731
Proc Natl Acad Sci U S A. 2012 May 8;109(19):7391-6
pubmed: 22517755
Evol Appl. 2019 Aug 27;12(10):1912-1930
pubmed: 31700535
Biochim Biophys Acta. 2010 Feb;1797(2):113-28
pubmed: 19761752
Curr Protoc Bioinformatics. 2013 Dec;44:1.23.1-26
pubmed: 25489354
Nat Commun. 2018 Oct 29;9(1):4500
pubmed: 30374105
Biochim Biophys Acta. 2012 Jun;1817(6):851-62
pubmed: 21924235
Cell. 2017 Sep 7;170(6):1247-1257.e12
pubmed: 28844695

Auteurs

Galya V Klink (GV)

Sector of Molecular Evolution, Institute for Information Transmission Problems (Kharkevich Institute) of the Russian Academy of Sciences, Moscow, Russian Federation.

Hannah O'Keefe (H)

Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK.

Amrita Gogna (A)

Biosciences Institute, Newcastle University, Newcastle upon Tyne, UK.

Georgii A Bazykin (GA)

Sector of Molecular Evolution, Institute for Information Transmission Problems (Kharkevich Institute) of the Russian Academy of Sciences, Moscow, Russian Federation. G.Bazykin@skoltech.ru.
Center of Life Sciences, Skolkovo Institute of Science and Technology, Skolkovo, Russian Federation. G.Bazykin@skoltech.ru.

Joanna L Elson (JL)

Biosciences Institute, Newcastle University, Newcastle upon Tyne, UK. J.l.Elson@ncl.ac.uk.
Human Metabolomics, North-West University, Potchefstroom, South Africa. J.l.Elson@ncl.ac.uk.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH